What are the fundraising trends in the digital health market?

In our digital health market deck, you will find everything you need to understand the market

This chart, featured in our digital health market deck, shows how revenue is split across customer segments in the digital health market

Is more or less capital going into the digital health market?

More capital is going into the digital health market in year-to-date 2026 than went into the same window in 2025 or 2024. The current year-to-date dataset shows $2.69B across 63 disclosed equity deals, compared with $1.66B across 18 deals in year-to-date 2025 and $1.11B across 19 deals in year-to-date 2024.

The first thing to notice is that this is not just one giant round making the market look bigger. The largest year-to-date 2026 deal was $250M, and it represented 9.3% of total capital. In year-to-date 2025, the largest deal represented 19.3% of capital, so the 2026 total is less dependent on one outlier.

The stronger signal is breadth. The digital health market moved from 18 qualifying deals in the comparable 2025 window to 63 deals in year-to-date 2026. That means the funding recovery is showing up in company count, not only in headline dollars.

There is also a useful full-year comparison. Full-year 2025 produced $2.85B across 39 deals, while year-to-date 2026 has already reached $2.69B across 63 deals. The practical takeaway is that 2026 is already close to the full-year 2025 capital level, but with far more companies represented.

For a fuller view of how digital health capital is moving across categories, stages, and regions, see the full digital health market report.

Is digital health funding driven by more deals or larger rounds?

Digital health funding in 2026 is being driven more by deal volume than by larger typical rounds. The market has 63 qualifying year-to-date deals, far above the 18 deals in the comparable 2025 period, while the median round fell from $37.5M in year-to-date 2025 to $21.0M in year-to-date 2026.

That difference changes how the market should be read. A founder raising a normal digital health round is not necessarily seeing a larger check than last year. What has changed is that many more companies are getting through the funding filter.

The average round in year-to-date 2026 is $42.7M, about twice the median. That tells us the market still has a meaningful top end, but the typical company is much closer to a $20M raise than a $40M raise.

The deal-size distribution reinforces the same point. Year-to-date 2026 had 28 deals in the $5M to $20M range and 19 deals in the $20M to $50M range, compared with 13 deals at $50M or more. The center of the market is broad institutional financing, not only mega-rounds.

Is digital health capital moving toward later-stage or earlier-stage companies?

Digital health capital is moving toward later-stage companies by dollars, while deal activity is still heavily concentrated at Series A and seed. In year-to-date 2026, late-stage rounds from Series B onward captured $1.58B, or 58.6% of capital, while seed and Series A together captured 32.9%.

By deal count, however, the market looks much earlier. Series A alone accounted for 25 of 63 deals, and seed added another 14. That means 39 of 63 qualifying deals were seed or Series A.

The honest interpretation is that the digital health market is running two markets at once. One market is funding many early institutional rounds around workflow AI, care navigation, patient access, and health data infrastructure. The other is reserving the biggest checks for scaled platforms with payer, provider, or clinical distribution.

Series D+ rounds show the late-stage capital pull most clearly. They represented only 6 of 63 deals but captured $918M, or 34.1% of capital. That is the clearest sign that investors are still willing to write large checks when a digital health company has already proven adoption and scale.

This chart, featured in our digital health market deck, compares the main business model options for digital health SaaS platforms

Is the digital health market maturing or still experimental?

The digital health market is maturing, but it is not evenly mature across all categories. The strongest evidence of maturity is that follow-on rounds captured 87.8% of year-to-date 2026 capital, which means most money is going to companies that had already proved enough to raise before.

At the same time, the digital health market still has a real formation layer. First financings represented 16 of 63 deals, or 25.4% of deal count. That is not a market where new company creation has stopped.

The difference is check size. First financings captured only $328.3M out of $2.69B, or 12.2% of capital. Investors are willing to start new digital health companies, but they are usually doing it with smaller checks than they give to established platforms.

The market is also maturing in what it rewards. Companies that attach AI to concrete operational workflows, such as claims, documentation, prior authorization, scheduling, care navigation, patient records, or revenue cycle, are more credible than companies selling generic health engagement or generic AI.

The practical takeaway is that digital health is no longer an experimental app category. It is becoming a healthcare operations and infrastructure market, with experimentation still happening at the edges.

Are new startups still entering the digital health market?

Yes, new startups are still entering the digital health market, but they are not receiving most of the capital. In year-to-date 2026, first financings accounted for 16 of 63 deals, or 25.4% of the total, while follow-ons accounted for the other 47 deals.

This is a stronger new-entrant signal than the comparable 2025 window, when first financings were only 11.1% of deals and 6.3% of capital. The 2026 market is therefore broader at the bottom than the 2025 market was.

The new entrants are concentrated around modern digital health infrastructure rather than generic consumer apps. Seed and first-financing examples include AI workflow software, patient-facing clinical agents, care advocacy, controlled AI agent platforms, health data systems, and remote monitoring tools.

But the capital split is still selective. First financings captured 12.2% of year-to-date 2026 dollars, which means the big money still belongs to companies with prior proof points. New companies can enter, but they need to earn larger follow-on rounds later.

For a deeper breakdown of first financings, follow-on rounds, and where new digital health company formation is happening, see the digital health market deck.

Are more investors entering the digital health market?

More investors are participating in the digital health market in 2026, and the investor base looks meaningfully broader than in 2025. The year-to-date 2026 dataset includes 198 unique disclosed investors and 52 unique tier-1 investors, compared with about 66 disclosed investors and about 23 tier-1 investors in the comparable 2025 window.

That expansion matters because it supports the idea that the market is broader, not just hotter. More companies are raising, and more investor groups are willing to participate in digital health rounds.

The most active repeat investors in year-to-date 2026 were General Catalyst with 5 deals, GV with 4, Kleiner Perkins with 4, and Andreessen Horowitz, NEA, Transformation Capital, Twelve Below, Y Combinator, and AlleyCorp with 3 each. This is a much denser repeat-investor map than the year-to-date 2025 subset, where CVS Health Ventures was the only investor with more than one deal under the normalization used.

The real signal is that digital health has become investable for both healthcare specialists and broad technology investors. AI, provider operations, payer workflows, and healthcare data infrastructure are themes that generalist venture firms can underwrite more easily than niche clinical-services models.

This chart, featured in our digital health market deck, shows annual funding in digital health startups

Are top investors getting more or less active in digital health?

Top investors are getting more active in the digital health market in 2026. The year-to-date 2026 dataset shows repeated participation from General Catalyst, GV, Kleiner Perkins, Andreessen Horowitz, NEA, Transformation Capital, Y Combinator, and other recognizable venture or healthcare investors.

This is a clear change from the comparable 2025 window. In year-to-date 2025, only CVS Health Ventures appeared more than once in the strict investor ranking. In year-to-date 2026, the list of repeat investors is much longer.

The pattern is not random. Top investors are clustering around healthcare AI, clinical workflow, payer/provider infrastructure, care navigation, and virtual care models with clearer reimbursement or distribution logic. They are not simply backing anything labeled digital health.

The practical interpretation is that top investors are active where the buyer, pain point, and budget owner are obvious. In digital health, that usually means provider administration, payer operations, clinical workflow, care coordination, or specialty care economics.

Which digital health subcategories are gaining momentum?

Clinical Workflow Software is the clearest digital health subcategory gaining momentum. It accounted for 41.3% of year-to-date 2026 deals and 38.2% of capital, making it the largest category by both measures.

This is not just a continuation of 2025. Clinical Workflow Software was already strong in 2025, with 46.2% of full-year deals and 49.1% of capital, but year-to-date 2026 shows the theme broadening into many more companies. The category now includes documentation, claims, denial management, scheduling, prior authorization, chart review, front-office automation, and clinical decision support.

Virtual Care Platforms are also gaining renewed capital momentum. They captured 30.8% of year-to-date 2026 capital versus only 2.2% of full-year 2025 capital. That does not mean generic telehealth is back; it means specialized virtual care with chronic, psychiatric, women’s health, obesity, and integrated-care economics is investable again.

Care Navigation Platforms are another strong signal. They represented only 9.5% of deals but captured 13.4% of capital, with a $45.0M median round. That suggests navigation becomes fundable when it is tied to measurable cost redirection, provider quality, patient advocacy, or specialty-care access.

We cover these category shifts in more detail in the market report covering digital health subcategories.

Which digital health subcategories are losing momentum?

Patient Engagement Tools are the clearest relative laggard in the current digital health market. In year-to-date 2026, they produced 7.9% of deals but only 3.9% of capital, which means the category is underweight on dollars.

This does not mean patient engagement is uninvestable. It means engagement alone is not enough. The fundable version needs clinical oversight, reimbursement, payer distribution, life-sciences workflow, therapy access, or a measurable operating outcome.

Remote Monitoring Solutions also remain smaller than the strongest narratives around devices might suggest. The category produced 6 deals and $174.6M in year-to-date 2026, with a median round of $20.5M. That is respectable, but it is not the center of the market.

Health Data Infrastructure also became less dominant than it was in year-to-date 2025. In the 2025 comparable window, the category captured 37.7% of capital, helped by large platform rounds. In year-to-date 2026, it captured 7.2%, which suggests that infrastructure is still important but no longer absorbing the largest share of dollars.

This chart, featured in our digital health market deck, shows how Hinge Health captured share in digital health

Which regions are gaining momentum in digital health funding?

Europe is gaining momentum in digital health funding by capital share, even though North America still dominates the market. Europe captured $278.8M, or 10.4% of year-to-date 2026 capital, compared with zero qualifying capital in the comparable 2025 year-to-date window under this dataset.

Oviva is the main reason Europe looks stronger. Its $220M round reshaped the regional profile and shows that European digital health companies can still command platform-scale financing when the model combines chronic care, reimbursement, clinical delivery, and technology.

Asia-Pacific also remains visible, but smaller. It produced 3 year-to-date 2026 deals and $45.8M of capital, compared with 1 deal and $16.6M in the comparable 2025 window. The region is gaining in deal count, but not yet at the scale needed to challenge North America.

The practical takeaway is that digital health is becoming more geographically visible, but large public equity rounds are still concentrated in a small set of regions. Europe has the stronger 2026 capital signal; Asia-Pacific has a modest formation signal.

Which regions are losing momentum in digital health funding?

Latin America, the Middle East, and Africa are not visible in this public digital health funding dataset. In year-to-date 2026, all three regions had zero qualifying disclosed equity deals under the pure-play, $300,000-plus filter.

That should not be overread as proof that nothing is happening in those regions. It is also a disclosure signal. Public venture rounds in digital health are easier to capture in North America and Europe than in markets where private, undisclosed, or grant-like financing is more common.

Asia-Pacific also lost momentum in capital share versus full-year 2025. In 2025, Asia-Pacific represented 11.6% of full-year capital, helped by several larger AI and digital health rounds. In year-to-date 2026, the region represented only 1.7% of capital.

The real regional loser is not a single active region but the long tail of underreported markets. Under this methodology, global digital health funding remains a North America-led market with selective European and Asia-Pacific exceptions.

Is digital health becoming more global or regionally concentrated?

Digital health is becoming somewhat more global by deal presence, but it remains regionally concentrated by dollars. Year-to-date 2026 includes North America, Europe, and Asia-Pacific deals, yet North America still captured 87.9% of capital and 88.9% of deal count.

This concentration has been consistent across the dataset. North America represented 93.6% of 2024 capital, 87.8% of full-year 2025 capital, and 87.9% of year-to-date 2026 capital. The percentage moves, but the basic structure does not.

Europe’s 2026 capital share is more meaningful than its deal count because Oviva alone made the region look much larger. Without one platform-scale European round, the region would look like a small set of mid-sized raises.

The honest interpretation is that digital health is global as an innovation category, but not yet global as a disclosed equity funding market. The companies and use cases are spreading, but the biggest checks are still written mostly into North American companies.

For the regional split across North America, Europe, Asia-Pacific, and the underrepresented regions, see the full market view on digital health regions.

This chart, featured in our digital health market deck, shows how remote care platforms have driven growth in the digital health market over time

Is digital health capital moving toward proven winners or new opportunities?

Digital health capital is moving more toward proven winners than new opportunities when measured by dollars. In year-to-date 2026, follow-on rounds captured 87.8% of capital, while first financings captured only 12.2%.

By deal count, the market is more balanced. First financings represented 25.4% of deals, so there is still meaningful company formation. But the larger checks are clearly going to companies that have already raised before.

This pattern is visible across categories. Clinical Workflow Software had 7 first financings and 19 follow-ons, while Virtual Care Platforms had 2 first financings and 11 follow-ons. Even in the hottest categories, the capital pool is tilted toward companies with prior traction.

The practical takeaway is that the digital health market is not closed to new startups, but new entrants need tight proof points. Investors are more comfortable scaling a company that has already shown workflow adoption, payer/provider demand, or clinical operating leverage.

Is the digital health market becoming winner-takes-most?

The digital health market is concentrated, but it is not fully winner-takes-most. In year-to-date 2026, the top 10 deals captured 55.0% of all capital, while the bottom half of deals still captured 14.2%.

That is a healthier concentration pattern than a market where two or three companies absorb nearly everything. The largest deal represented only 9.3% of total capital, and the top three represented 25.3%. So the top matters, but it does not define the whole market.

Compared with year-to-date 2025, the market is less top-heavy. In that period, the top 10 deals captured 91.4% of capital and the top three captured 51.0%. In year-to-date 2026, capital is spread across a much broader set of companies.

The practical interpretation is that digital health has moved from a narrower platform-round market into a broader institutional funding market. There are still large winners, but the middle of the market is alive.

Is the next wave of digital health winners becoming visible?

Yes, the next wave of digital health winners is becoming visible, and it is centered on healthcare operating infrastructure. The strongest funded companies are not generic wellness apps; they are platforms that sit inside clinical, payer, provider, patient access, or administrative workflows.

The category mix makes that clear. Clinical Workflow Software, Care Navigation Platforms, and Health Data Infrastructure together represent a large share of the market’s most important workflow and infrastructure bets. These companies often solve problems that already have budgets: documentation, claims, coding, prior authorization, scheduling, referrals, records, network quality, and cost redirection.

Virtual Care winners are also becoming more specific. The strongest examples are not broad telehealth marketplaces, but focused care models around psychiatry, women’s health, chronic care, obesity, oncology support, and integrated primary care.

The most useful filter is whether the company controls a painful workflow where the buyer, data, and return on investment are visible. If those three pieces are present, the digital health market is much more willing to fund the company at scale.

For deeper analysis of the companies and models that are becoming most fundable, see the deeper analysis of the digital health market.

As this chart shows, and as featured in our digital health market deck, search interest in longevity apps and related topics has been increasing

Is the digital health funding landscape fragmenting or consolidating?

The digital health funding landscape is broadening at the company and investor level while consolidating around a few dominant themes. Year-to-date 2026 has 63 deals and 198 disclosed investors, so the market is much more fragmented in participation than it was in the comparable 2025 window.

But thematically, the market is consolidating around healthcare operations. The repeated patterns are clinical workflow, payer infrastructure, provider administration, care navigation, specialty care, patient access, and AI systems that automate specific healthcare bottlenecks.

The category structure shows the same balance. Clinical Workflow Software dominates deal count, while Virtual Care Platforms and Care Navigation Platforms punch above their deal-share weight in capital. That means the funding map is broad, but the logic behind the largest checks is fairly consistent.

The right way to describe the current state is selective breadth. More companies and more investors are active, but the market is not equally interested in every kind of digital health idea.

Where is investor attention shifting in digital health?

Investor attention in digital health is shifting toward workflow AI, care navigation, and healthcare operating infrastructure. The strongest 2026 signals sit in companies that reduce administrative burden, improve clinical workflow, redirect patients to better care, or turn fragmented data into operational action.

The phrase “AI agent” appears across many funded companies, but the dataset shows that the label matters only when attached to a real workflow. Claims review, denial management, prior authorization, chart review, medical records, scheduling, referrals, revenue cycle, and patient communication are the credible use cases.

Investor attention is also shifting away from broad consumer engagement. Patient Engagement Tools still raise money, but their capital share is low unless the product connects to clinical oversight, reimbursable therapy, life-sciences access, or measurable workflow improvement.

The broader read is that digital health is becoming less about replacing healthcare encounters and more about rebuilding the infrastructure around them. The winning story is not “more digital care” in the abstract; it is “less friction in a specific healthcare workflow.”

For ongoing tracking of how investor attention is moving across workflow AI, virtual care, navigation, monitoring, engagement, and health data infrastructure, see the digital health market report.

This chart, featured in our digital health market deck, shows how remote patient monitoring platform technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.